New drug targeting DNA repair shows promise in range of advanced cancers
A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial—highlighting the […]
» Read moreHome »
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of […] T cells represent a key component of our immune system, and play a critical role in protecting us against harmful […] The most deadly forms of alcohol-related liver disease appear to be on the rise in the U.S., a new study […] In a new study, Yale Cancer Center scientists have demonstrated a powerful method to analyze how tumor cells are altered […] (HealthDay)—The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the […] Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according […] Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are […] In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP […]
Immunotherapy improves survival in advanced bladder cancer patients
Advanced imaging tips T cell target recognition on its head
Advanced alcohol-related liver disease on rise in US, study finds
New technique may improve detection and treatment of advanced brain cancer
FDA approves pembrolizumab plus axitinib for advanced RCC
Immunotherapy effective as first-line treatment for advanced head and neck cancer
Targeted drugs for advanced cancer move from specialist units to community setting
PARP inhibitor improves progression-free survival in patients with advanced breast cancers
